Turning Point Therapeutics Reports Early Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib, Provides Regulatory Update

On August 19, 2020 Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, reported early interim data from the registrational Phase 2 TRIDENT-1 study of lead drug candidate, repotrectinib, and announced recent regulatory feedback from the Food and Drug Administration (FDA) on the TRIDENT-1 trial design (Press release, Turning Point Therapeutics, AUG 19, 2020, View Source [SID1234563897]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very encouraged by the early interim data from the Phase 2 TRIDENT-1 study as they reaffirm our belief that repotrectinib has the potential to be the best-in-class treatment for patients with ROS1- or NTRK-driven tumors, including patients who are TKI-naïve and TKI-pretreated," said Athena Countouriotis, M.D., president and chief executive officer. "Additionally, we recently received FDA feedback that may provide a faster path to potential approval, including pooling of patients from the Phase 1 portion of the study treated at the recommended dose of repotrectinib with patients treated in the Phase 2 portion, and cohort sample size modifications. Hence, we are modifying the TRIDENT-1 study sample sizes and adding new interim analyses that may support approval into two of our ROS1-positive TKI-pretreated patient cohorts. We now anticipate providing an update in early 2021 on the overall study timelines."

Early Interim Phase 2 Data from TRIDENT-1 Study
The early Phase 2 TRIDENT-1 dataset utilizing a July 10, 2020 data cutoff includes the first 39 treated patients who have had at least one post-baseline scan. Responses were confirmed with a subsequent scan at least 28 days later per RECIST 1.1 and were determined by physician assessment. Patients were enrolled across six countries.

Phase 2 Preliminary Efficacy Analysis (n=39)

Across all cohorts reported, median follow-up was 3.6 months (range: 0.4 – 7.4+), and median duration of treatment was 3.7 months (range: 0.7-8.2+)

In the ROS1-positive TKI-naïve non-small cell lung cancer (NSCLC) population (EXP-1: n=7):

Six patients achieved a confirmed response for an Objective Response Rate (ORR) of 86 percent. The duration of response ranged from 0.9+ to 2.0+ months and all patients who achieved a response remained in a response at the time of the data cutoff.

Since the July 10 data cutoff, the seventh patient in this cohort has achieved an unconfirmed partial response and remains on treatment awaiting a confirmatory scan.

In the ROS1-positive NSCLC population pretreated with one prior TKI with prior chemotherapy (EXP-2: n=5):

Two patients achieved a confirmed response for an ORR of 40 percent. The durations of response were 4.5 and 5.6+ months at the time of the data cutoff.

In the ROS1-positive NSCLC population pretreated with one prior TKI without prior chemotherapy (EXP-4: n=6):

Four patients achieved a confirmed response for an ORR of 67 percent. The duration of response ranged from 1.0+ to 5.7+ months with all four patients remaining in a response at the time of the data cutoff.

In the ROS1-positive NSCLC population pretreated with two prior TKIs with prior chemotherapy (EXP-3: n=10):

No objective responses were observed within this heavily pretreated fourth-line patient population, yet five patients achieved stable disease.

The company recently recommended to the study’s data monitoring committee (DMC) that expansion cohort three (EXP-3) be modified to remove the requirement for prior chemotherapy based on limited activity to date in this fourth-line patient cohort. The company’s intent is to only support third-line patients in this cohort going forward and to preserve the opportunity to evaluate these patients as the treatment landscape changes with less chemotherapy use. The DMC recommended the study proceed and agreed with the recommended change to cohort three.

In the ROS1-positive NSCLC population pretreated with two prior TKIs without prior chemotherapy (patients enrolled under the initial protocol and analyzed for efficacy in a separate cohort, EXP-Other: n=5):

Two patients achieved a confirmed response for an ORR of 40 percent. Both patients remained in a response with a duration of 1.9+ months at the time of the data cutoff.

In the NTRK-positive TKI-pretreated solid tumor population (EXP-6: n=6):
Three patients achieved a confirmed response for an ORR of 50 percent. The duration of response ranged from 1.7+ to 3.6+ months with all three patients remaining in a response at the time of the data cutoff.
Data from the Phase 1 (at all doses studied) and Phase 2 of the TRIDENT-1 study are summarized in the table below.

TRIDENT-1 Study of Repotrectinib
(Phase 2 Cohorts) Phase 1
July 22, 2019
Data Cutoff
All doses studied, BICR Phase 2
July 10, 2020
Data Cutoff
Phase 2 Dose, PI assessment

ORR
95% CI
ORR
95% CI

ROS1+ TKI-Naïve
(EXP-1)

91%
(10/11)

(59-100)

86%1
(6/7)

(42-100)

ROS1+ TKI-Pretreated 1-prior TKI, with prior platinum-based chemotherapy
(EXP- 2)

36%
(5/14)

(13-65)

40%
(2/5)

(5-85)

ROS1+ TKI-Pretreated,
without prior platinum-based chemotherapy
(EXP-4)

50%
(2/4) (7-93) 67%
(4/6) (22-96)

ROS1+ TKI-Pretreated 2-prior TKIs, without prior platinum-based chemotherapy 2
(EXP- Other)

0%
(0/1)

NA

40%
(2/5)

(5-85)

NTRK TKI-Pretreated
(EXP-6)

33%
(1/3)

(1-91)

50%
(3/6)

(12-88)
1 Since the July 10th data cutoff, the seventh patient in this cohort has achieved an unconfirmed partial response and remains on treatment awaiting a confirmatory scan.
2 Represents the planned modified EXP-3 cohort of patients previously treated with 2 prior TKIs without prior chemotherapy. In EXP-3 (Two prior TKIs with prior chemotherapy; N=10): No objective responses observed.

Data pooled from the Phase 1 (patients dosed at or above the Phase 2 dose) and Phase 2 portions of the TRIDENT-1 study are summarized in the table below.

TRIDENT-1 Study of Repotrectinib
(Phase 2 Cohorts) Phase 1 + 2 TRIDENT-1 Data Combined
(Phase 1 patients dosed at or above the Phase 2 dose)

ORR

95% CI

ROS1+ TKI-Naïve
(EXP-1)

86%1
(12/14)

(57-98)

ROS1+ TKI-Pretreated 1-prior TKI, with prior platinum-based chemotherapy
(EXP-2)

50%
(6/12)

(21-79)

ROS1+ TKI-Pretreated 1-prior TKI without prior platinum-based chemotherapy
(EXP-4)

67%
(6/9) (30-93)

ROS1 TKI-Pretreated 2-prior TKIs, without prior platinum-based chemotherapy 2
(EXP-Other)

33%
(2/6)

(4-78)

NTRK TKI-Pretreated (EXP-6)

43%
(3/7)

(10-82)
1 Since the July 10th data cutoff, one additional Phase 2 patient achieved an unconfirmed partial response and remains on treatment awaiting a confirmatory scan.
2 Represents the planned modified EXP-3 cohort of patients previously treated with 2 prior TKIs without prior chemotherapy. In EXP-3 (Two prior TKIs with prior chemotherapy; N=10): No objective responses observed.

Preliminary Safety Analysis (n=39)

A total of 39 ROS1- and NTRK-positive patients were treated with repotrectinib at a starting dose of 160 mg daily (QD), with 90 percent of patients escalating after 14 days to 160 mg twice daily (BID) per the study defined dose titration approach.

Repotrectinib was generally well tolerated. The majority of treatment emergent adverse events (TEAEs) were Grade 1 or 2. The TEAEs (any Grade) found in greater than 25 percent of patients were dizziness (62%), fatigue (39%), constipation (33%), dysgeusia (33%), and dyspnea (28%). There were no Grade 3 cases of dizziness and no cases of dizziness leading to treatment discontinuation.

Additionally, the majority of treatment related adverse events (TRAEs) were Grade 1 or 2. There were no Grade 4 or Grade 5 TRAEs.
Regulatory and Study Updates:
Turning Point also announced recent feedback received from the FDA and modifications the company is making to the study design that may accelerate the timelines to potential approval for repotrectinib. The FDA reiterated that the adequacy of the data to support approval will depend upon the observed ORR and the duration of response assessed in the context of available therapy in a risk-benefit analysis during NDA review.

These updates include:

Phase 2 cohort sample sizes to support potential approval may include Phase 1 patients treated at the recommended Phase 2 dose. The pooling of Phase 1 and Phase 2 data may shorten timelines to potential regulatory submission based on fewer patients from the Phase 2 portion of the study.

EXP-2 Cohort (ROS1 TKI-Pretreated with one prior TKI and one platinum-based regimen): The company plans to decrease the sample size from current target of 100 patients to 60 total patients with one formal interim analysis after approximately 30 patients. FDA provided guidance that 6 months of follow up may be sufficient to support approval.

EXP-4 Cohort (ROS1 TKI-Pretreated with one prior TKI and no prior chemotherapy): The company plans to increase the sample size to a target of 60 patients with one formal interim analysis after approximately 30 patients. Previously, EXP-4 was an exploratory cohort in this patient population. FDA provided guidance that 6 months of follow up may be sufficient to support approval.

EXP-5 and EXP-6 Cohorts (TRK TKI-Naïve and TKI-Pretreated): FDA provided guidance that 9 months and 6 months of follow up, respectively, from the last response may be sufficient to support approval. Previous guidance was 12 months for both patient cohorts.
Based on this FDA feedback and the subsequent sample size changes, the company is reviewing its timelines for when it expects the top-line interim analysis data sets will be achieved, and anticipates sharing those timelines as it gets closer to achieving full site activation in early 2021.

Webcast and Conference Call
Turning Point will host a webcast accompanied by a slide presentation to discuss the results at 8:00 a.m. EDT/5:00 a.m. PDT. Dr. Countouriotis will host the call, which will be accessible through the "Investors" section of tptherapeutics.com or by dialing (877) 388-2118 (in the United States) or (470) 495-9489 (outside the U.S.) using conference ID 5077833. A replay will be available through the "Investors" section of www.tptherapeutics.com.

Prescient Therapeutics is developing novel personalised therapies against a range of cancers – Small Caps

On August 19, 2020 Prescient Therapeutics (ASX: PTX) reported Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the company’s novel approach to treating cancer using targeted and cellular therapy (Press release, Prescient Therapeutics, AUG 19, 2020, View Source;utm_medium=rss&utm_campaign=prescient-therapeutics-is-developing-novel-personalised-therapies-against-a-range-of-cancers-small-caps [SID1234565490]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Prescient Therapeutics is the only ASX-listed company developing CAR-T technology, which is a type of cellular therapy that reprograms a cancer patient’s immune cells to recognise and destroy cancer.

The clinical stage oncology company recently announced it will be teaming up with the Peter MacCallum Cancer Centre to advance its cell therapy research, including next generation CAR-T.

BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis

On August 19, 2020 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, reported that a sufficient number of patients (~65% of the original planned sample size) have been enrolled in the ongoing GENESIS Phase 3 trial to allow for an interim efficacy analysis to take place in the second half of 2020 (Press release, BioLineRx, AUG 19, 2020, View Source [SID1234563853]). This ongoing registrational study is investigating motixafortide (BL-8040) for the mobilization of hematopoietic stem cells (HSCs) for autologous transplantation in patients with multiple myeloma. If the primary endpoint is met at the time of the interim analysis, the Company plans to immediately announce the cessation of further recruitment, without the need to enroll the full planned sample size. In this case, top-line results are expected in the first half of 2021, in order to maintain study blinding for all study endpoints, including those related to engraftment, for a period of 100 days subsequent to transplantation. If the primary endpoint is not reached in the interim analysis, the Company expects recruitment will continue until the originally planned sample size is met.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"A significantly lower than anticipated patient dropout rate in the GENESIS trial triggered our decision to conduct an interim efficacy analysis, for which we have now enrolled a sufficient number of patients," said Philip Serlin, Chief Executive Officer of BioLineRx. "Once this analysis is complete, we will have enough information to decide whether to cease further enrollment or continue until completion of the original target enrollment of 177 patients. We expect the interim analysis to be completed within the next few months."

The GENESIS trial was initiated in December 2017. GENESIS is a randomized, placebo-controlled, multicenter study, evaluating the safety, tolerability and efficacy of motixafortide and G-CSF, compared to placebo and G-CSF, for the mobilization of HSCs for autologous transplantation in multiple myeloma patients. The primary objective of the study is to demonstrate that motixafortide on top of G-CSF is superior to G-CSF alone in the ability of mobilize ≥ 6×106 CD34+ cells in up to two apheresis sessions. Secondary objectives include time to engraftment of neutrophils and platelets and durability of engraftment, as well as other efficacy and safety parameters

NW Bio Announces Completion of Further Data Gathering For Phase III Trial

On August 19, 2020 Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, reported that the remaining outstanding clinical trial data for the Company’s Phase 3 trial of DCVax-L for Glioblastoma brain cancer as described in the Company’s last report on July 24, 2020 has now been completed by the specialty analytics firms (Press release, Northwest Biotherapeutics, AUG 19, 2020, View Source [SID1234569920]). With this data now in hand, final quality control checking and confirmation are under way to enable Data Lock.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This further data involves specialty analytics such as genomic profiling for IDH mutations and certain imaging. The independent CRO managing the trial is now integrating this data into the overall trial database containing the clinical data from the trial sites that was already complete and locked as reported on July 24, 2020, in order to complete the overall trial dataset.

When Data Lock is reached, the independent statisticians will be given access to the unblinded dataset. The Company will remain blinded while the statisticians make the computations, converting the mass of raw data from the trial into formal tables and listings, and survival and progression measures, to report the trial results.

As previously reported, the statisticians’ work is estimated to take a couple of weeks. When their computations are completed, the Company will receive the results of those computations and thereby become unblinded. It is anticipated that the Company’s Scientific Advisory Board, the Steering Committee of the Trial and other key medical expert advisors will likewise receive the results, and thereby become unblinded as well.

The Company currently continues to anticipate reporting topline trial data in September, and anticipates providing further updates as the process progresses.

National Comprehensive Cancer Network® Adds Monjuvi® (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas

On August 18, 2020 MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (Nasdaq:INCY) reported that Monjuvi (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, has been included in the latest National Comprehensive Cancer Network Clinical Practice Guidelines (NCCN Guidelines) in Oncology for B-cell Lymphomas (Press release, Incyte, AUG 18, 2020, View Source [SID1234563774]). Specifically, the NCCN Guidelines in the United States now include Monjuvi in combination with lenalidomide with a Category 2A designation as an option for the treatment of previously-treated adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma who are ineligible for autologous stem cell transplant (ASCT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This press release features multimedia. View the full release here: View Source

"We are very gratified the NCCN acted quickly to include Monjuvi in combination with lenalidomide with a Category 2A designation in its Clinical Practice Guidelines in Oncology as a treatment for patients with relapsed or refractory DLBCL who are not candidates for transplant. This targeted therapeutic option helps address an immediate medical need for patients who previously had limited treatment options," said Dr. Malte Peters, Chief Research & Development Officer, MorphoSys. "There is no other FDA-approved second line treatment for these patients with a 2A designation within the NCCN guidelines."

The U.S. Food and Drug Administration (FDA) approved Monjuvi in combination with lenalidomide under accelerated approval on July 31, 2020, for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DBLCL arising from low grade lymphoma, and who are not eligible for ASCT. The approval was based on data from the MorphoSys-sponsored Phase 2 L-MIND study, an open label, multicenter single arm trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).1

The NCCN is a not-for-profit alliance of 30 leading cancer centers devoted to patient care, research and education. The intent of the NCCN Guidelines is to assist in the decision-making process of individuals involved in cancer care – including physicians, nurses, pharmacists, payers, patients and their families – with the ultimate goal of improving patient care and outcomes.

"The inclusion of Monjuvi in the NCCN Guidelines will help further inform healthcare providers of this advancement for patients," said Peg Squier, M.D., Group Vice President, U.S. Medical Affairs, Incyte. "We believe Monjuvi has the potential to address an urgent medical need for patients with relapsed or refractory DLBCL and are pleased that the NCCN has acknowledged the clinical benefit of this targeted therapeutic option."

DLBCL is the most common type of non-Hodgkin lymphoma in adults worldwide,2 characterized by rapidly growing masses of malignant B-cells in the lymph nodes, spleen, liver, bone marrow or other organs. It is an aggressive disease with about one in three patients not responding to initial therapy or relapsing thereafter.3 In the United States each year, approximately 10,000 patients are diagnosed with relapsed or refractory DLBCL who are not eligible for ASCT.4,5,6

The updated NCCN Guidelines are available at www.nccn.org.

NCCN and the NCCN Guidelines are registered trademarks of National Comprehensive Cancer Network.

About Monjuvi (tafasitamab-cxix)
Monjuvi is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

Monjuvi is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize Monjuvi globally. Monjuvi will be co-commercialized by Incyte and MorphoSys in the United States. Incyte has exclusive commercialization rights outside the United States.

A marketing authorization application (MAA) seeking the approval of tafasitamab in combination with lenalidomide in the EU has been validated by the European Medicines Agency (EMA) and is currently under review for the treatment of adult patients with relapsed or refractory DLBCL, including DLBCL arising from low grade lymphoma, who are not candidates for ASCT.

Tafasitamab-cxix is being clinically investigated as a therapeutic option in B-cell malignancies in a number of ongoing combination trials.

Monjuvi is a registered trademark of MorphoSys AG.
XmAb is a registered trademark of Xencor, Inc.

Important Safety Information
What are the possible side effects of MONJUVI?
MONJUVI may cause serious side effects, including:

Infusion reactions. Your healthcare provider will monitor you for infusion reactions during your infusion of MONJUVI. Tell your healthcare provider right away if you get chills, flushing, headache, or shortness of breath during an infusion of MONJUVI.
Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with MONJUVI, but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with MONJUVI. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or any bruising or bleeding.
Infections. Serious infections, including infections that can cause death, have happened in people during treatments with MONJUVI and after the last dose. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or develop any signs and symptoms of an infection.
The most common side effects of MONJUVI include:

Feeling tired or weak
Diarrhea
Cough
Fever
Swelling of lower legs or hands
Respiratory tract infection
Decreased appetite
These are not all the possible side effects of MONJUVI.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before you receive MONJUVI, tell your healthcare provider about all your medical conditions, including if you:

Have an active infection or have had one recently.
Are pregnant or plan to become pregnant. MONJUVI may harm your unborn baby. You should not become pregnant during treatment with MONJUVI. Do not receive treatment with MONJUVI in combination with lenalidomide if you are pregnant because lenalidomide can cause birth defects and death of your unborn baby.
You should use an effective method of birth control (contraception) during treatment and for at least 3 months after your final dose of MONJUVI.
Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with MONJUVI.
Are breastfeeding or plan to breastfeed. It is not known if MONJUVI passes into your breastmilk. Do not breastfeed during treatment for at least 3 months after your last dose of MONJUVI.
You should also read the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.

Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.